Transmural Healing Evaluated by Bowel Sonography in Patients with Crohn’s Disease on Maintenance Treatment with Biologics
Open Access
- 1 July 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 19 (9) , 1928-1934
Abstract
Background. Both thiopurines and anti-tumor necrosis factor (TNF) α agents are effective for treating Crohn’s disease (CD) as they can induce clinical remissionKeywords
This publication has 41 references indexed in Scilit:
- Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-AnalysisAmerican Journal of Gastroenterology, 2011
- The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease☆Digestive and Liver Disease, 2011
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current managementJournal of Crohn's and Colitis, 2010
- Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's DiseaseGastroenterology, 2010
- Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs diseaseInflammatory Bowel Diseases, 2009
- Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled TrialsClinical Gastroenterology and Hepatology, 2008
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trialThe Lancet, 2008
- Inflammatory bowel disease: clinical aspects and established and evolving therapiesThe Lancet, 2007
- REGIONAL ILEITISJAMA, 1932